Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for five approved new animal drug applications (NADAs) from Merial Ltd., to Huvepharma AD.

DATES:

This rule is effective October 25, 2007.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: david.newkirk@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640 has informed FDA that it has transferred ownership of, and all rights and interest in, the following five approved NADAs to Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria:

Application No.Trade name(s)
012-350AMPROVINE (amprolium) 25% Type A Medicated Article; CORID (amprolium) 25% Type A Medicated Article
013-149AMPROVINE (amprolium) 9.6% Solution
013-461Broiler PMX No. 1620 (amprolium/ethopabate)
033-165AMPROVINE (amprolium) 20% Soluble Powder; CORID (amprolium) 20% Soluble Powder
034-393COYDEN 25 (clopidol); Lerbek 25

Accordingly, the agency is amending the regulations in 21 CFR 520.100, 558.55, 558.58, and 558.175 to reflect the transfer of ownership.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

2. In paragraph (b)(1) of § 520.100, remove “050604” and in its place add “016592”.

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

4. In paragraph (a) of § 558.55, remove “050604” and in its place add “No. 016592”.

End Amendment Part Start Amendment Part

5. In § 558.58, in the table in paragraph (e)(1)(i), in the first entry, in the “Sponsor” column, add “050604” and “016592”; add paragraph (a)(3); and revise paragraph (b) to read as follows:

End Amendment Part
Amprolium and ethopabate.

(a) * * *

(3) 25 percent amprolium and 0.8 percent ethopabate.

(b) Approvals. See § 510.600(c) of this chapter.

(1) No. 050604 for products described in paragraph (a) of this section.

(2) No. 016592 for product described in paragraph (a)(3) of this section.

[Amended]
Start Amendment Part

6. In § 558.175, in paragraph (b) and in the table in paragraph (d)(1) in the “Sponsor” column, remove “050604” and in its place add “016592”.

End Amendment Part Start Signature

Dated: October 17, 2007.

Bernadette Dunham,

Deputy Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. E7-21057 Filed 10-24-07; 8:45 am]

BILLING CODE 4160-01-S